Form 4: Puma Biotech CEO Sells $200K in Stock Under 10b5-1 Plan

Puma Biotechnology's President and CEO, Alan H. Auerbach, sold 34,950 shares of common stock for approximately $204,000 through a pre-arranged 10b5-1 trading plan.

Summary

• Alan H. Auerbach, President and CEO, Director, and 10% Owner of Puma Biotechnology, Inc. (PBYI), reported sales of common stock.
• On January 6, 2026, Auerbach disposed of 16,938 shares of common stock at a price of $5.844 per share.
• On January 7, 2026, Auerbach disposed of an additional 18,012 shares of common stock at a price of $5.879 per share.
• These transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan, adopted on December 17, 2020.
• Following these transactions, Auerbach beneficially owns 7,145,951 shares of Puma Biotechnology common stock directly.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by the CEO, Director, and 10% owner, which can signal a lack of confidence, despite being executed under a 10b5-1 plan.

Negatives

• The President and CEO, who is also a Director and 10% owner, sold a total of 34,950 shares of company stock.
• Insider selling, even under a 10b5-1 plan, can be perceived by investors as a lack of confidence in the company's near-term prospects or valuation.

Future Outlook

NA

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the insider selling as a bearish signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

The sale of shares by the President and CEO, a significant insider, typically warrants a cautious approach. While executed under a pre-arranged 10b5-1 plan, which mitigates the immediate negative perception of opportunistic selling, it still represents a reduction in insider ownership. Investors should monitor future insider activity and company performance, but this transaction alone does not present a strong 'buy' signal, nor does it necessarily indicate a fundamental deterioration warranting a 'sell' without further information.

Keywords

PBYI, Puma Biotechnology, Alan H. Auerbach, Insider Selling, Form 4, Stock Sale, 10b5-1 Plan, CEO